Puma Biotechnology, Inc. (PBYI)
10.22
+0.39
(+3.97%)
USD |
NASDAQ |
Oct 19, 16:00
10.22
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Net Income (Quarterly) : 8.189M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.189M |
| March 31, 2026 | -3.753M |
| December 31, 2025 | 13.44M |
| September 30, 2025 | 8.844M |
| June 30, 2025 | 5.855M |
| March 31, 2025 | 2.974M |
| December 31, 2024 | 19.30M |
| September 30, 2024 | 20.32M |
| June 30, 2024 | -4.529M |
| March 31, 2024 | -4.815M |
| December 31, 2023 | 12.27M |
| September 30, 2023 | 5.796M |
| June 30, 2023 | 2.126M |
| March 31, 2023 | 1.401M |
| December 31, 2022 | -5.606M |
| September 30, 2022 | -0.36M |
| June 30, 2022 | 9.371M |
| March 31, 2022 | -3.403M |
| December 31, 2021 | 4.224M |
| September 30, 2021 | -44.67M |
| June 30, 2021 | -5.106M |
| March 31, 2021 | 16.53M |
| December 31, 2020 | -15.00M |
| September 30, 2020 | -31.46M |
| June 30, 2020 | 3.395M |
| Date | Value |
|---|---|
| March 31, 2020 | -16.93M |
| December 31, 2019 | -11.20M |
| September 30, 2019 | -16.88M |
| June 30, 2019 | -37.42M |
| March 31, 2019 | -10.09M |
| December 31, 2018 | -30.70M |
| September 30, 2018 | -14.20M |
| June 30, 2018 | -44.34M |
| March 31, 2018 | -24.34M |
| December 31, 2017 | -64.10M |
| September 30, 2017 | -77.18M |
| June 30, 2017 | -77.83M |
| March 31, 2017 | -72.86M |
| December 31, 2016 | -72.70M |
| September 30, 2016 | -65.78M |
| June 30, 2016 | -66.60M |
| March 31, 2016 | -70.97M |
| December 31, 2015 | -61.70M |
| September 30, 2015 | -60.42M |
| June 30, 2015 | -64.69M |
| March 31, 2015 | -52.45M |
| December 31, 2014 | -47.50M |
| September 30, 2014 | -35.84M |
| June 30, 2014 | -38.84M |
| March 31, 2014 | -19.79M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 3.309M |
| Arcutis Biotherapeutics, Inc. | 15.01M |
| Olema Pharmaceuticals, Inc. | -63.20M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 56.50M |
| Total Expenses (Quarterly) | 48.31M |
| EPS Diluted (Quarterly) | 0.1557 |
| Enterprise Value | 413.25M |
| Gross Profit Margin (Quarterly) | 77.92% |
| Profit Margin (Quarterly) | 14.49% |
| Earnings Yield | 5.05% |
| Operating Earnings Yield | 5.79% |
| Normalized Earnings Yield | 5.053 |